Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose of the combination therapy of
sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients
with advanced hepatocellular carcinoma (Phase I), and to evaluate the efficacy of this
combination therapy in the recommended dose (Phase II).